Slingshot members are tracking this event:

FDAA approves Merck & co. (MRK) product KEYTRUDA® (pembrolizumab) for the treatment of non-squamous non-small cell lung cance (NSCLC)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
MRK Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 10, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Non-squamous Non-small Cell Lung Cance, Nsclc, Keytruda, Pembrolizumab